The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Tegoprubart - kidney transplantation programs | 35,994 | - |
| Tegoprubart - other development programs | -168 | - |
| Manufacturing | 14,974 | - |
| Personnel-related expenses | 14,526 | - |
| Stock-based compensation | 10,451 | - |
| Other segment items | 7,474 | - |
| Other income, net | 4,220 | - |
| Change in fair value of warrant liabilities | -33,449 | - |
| Provision for income taxes | 35 | - |
| Net income (loss) | -45,617 | -36,184 |
| Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds | - | -30,900 |
| Non-cash lease expense | 313 | - |
| Accretion of investment discounts | -1,696 | -2,799 |
| Stock-based compensation | 10,451 | 13,122 |
| Gain on lease termination | - | 10 |
| Change in fair value of warrant liabilities | -33,449 | - |
| Amortization of operating lease right-of-use asset | - | 359 |
| Deferred tax provision | 5 | 431 |
| Prepaid expenses and other assets | -1,241 | -1,298 |
| Accounts payable, accrued expenses and other liabilities | 6,724 | 7,751 |
| Operating lease liabilities | -313 | -339 |
| Net cash used in operating activities | -62,341 | -47,271 |
| Purchase of available-for-sale short-term investments | 161,132 | 156,131 |
| Proceeds from maturities of available-for-sale short-term investments | 171,925 | 85,817 |
| Net cash provided by (used in) investing activities | 10,793 | -70,314 |
| Proceeds from issuances of common stock and pre-funded warrants, net | 53,577 | 133,307 |
| Proceeds from exercise of stock options | 230 | 215 |
| Net cash provided by financing activities | 53,807 | 133,522 |
| Net change in cash and cash equivalents | 2,259 | 15,937 |
| Cash and cash equivalents at beginning of year | 20,549 | - |
| Cash and cash equivalents at end of year | 22,808 | - |
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)